Newsroom

Sorted by: Latest

-

JBS to Host Third Quarter 2026 Earnings Call on November 10, 2026

AMSTELVEEN, Netherlands--(BUSINESS WIRE)--JBS N.V. (NYSE: JBS; B3: JBSS32) announced today that it will release its third quarter 2026 financial results after the U.S. market closes on Monday, November 9, 2026. The company’s executives will review the results on a conference call and webcast on Tuesday, November 10, 2026, at 9:00 a.m. Eastern Time (11:00 a.m. Brasília Time). Prepared remarks regarding the company’s financial and operational results will be followed by a question-and-answer sess...
-

Arrowstreet Capital Ltd UK Regulatory Announcement: Form 8.3 SThree PLC

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Arrowstreet Capital, Limited Partnership (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Farallon Capital Management, L.L.C. UK Regulatory Announcement: Form 8.3

SAN FRANCISCO--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Farallon Capital Management, L.L.C. (on behalf of funds managed jointly with Farallon Capital Europe LLP and Farallon Partners, L.L.C.) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming...
-

Hunt Military Communities, U.S. Navy, Department of War, and Community Leaders Celebrate Closing of Homeport Hampton Roads Phase II, Launching Housing Program for Unaccompanied Sailors

NORFOLK, Va.--(BUSINESS WIRE)--Hunt Military Communities (HMC) today joined Navy and Department of War leaders, elected officials, and community partners to celebrate the closing of Homeport Hampton Roads Phase II, a $1.7 billion development program with the Department of the Navy that will construct approximately 5,470 new beds and improve or integrate approximately 2,600 existing beds for unaccompanied Sailors at Naval Station Norfolk, Joint Expeditionary Base Little Creek, Naval Air Station...
-

DentalXChange Names Scott Hampel President

IRVINE, Calif.--(BUSINESS WIRE)--DentalXChange names healthcare technology veteran Scott Hampel President to lead product, operations, and engineering as it accelerates growth....
-

Oregon Bancorp Announces Quarterly Earnings

SALEM, Ore.--(BUSINESS WIRE)--Oregon Bancorp, Inc. (OTCBB: ORBN) (the “Company”), parent company of Willamette Valley Bank, reported net income of $746 thousand, or $0.30 per share, for the third quarter of 2026, compared to net income of $604 thousand, or $0.24 per share, for the second quarter of 2026. The Company generated a return on average assets of 0.6% and a return on average equity of 4.0% for the quarter. Third-quarter results included $212 thousand of trailing expenses associated wit...
-

Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled “Characterising the efficacy of multi-node PI3K/AKT/mTOR pathway inhibition with serabelisib and sapanisertib (PIKTOR) in combination with SERDs and a CDK4/6...
-

Convergent Therapeutics to Present Phase 2 Results Demonstrating Potent Anti-Tumor Activity of CONV01-α in Lu-PSMA-Naïve Prostate Cancer at ESMO Congress 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for the treatment of cancer, today announced compelling results from Part 2 of the Phase 2 CONVERGE-01 study evaluating Ac-225 rosopatamab tetraxetan (CONV01-α) in patients with Lu-PSMA-naïve, androgen pathway modulator-resistant (APMR) prostate cancer. In the study, CONV01-α demonstrated potent anti-tumor activity, including deep prostate speci...
-

Health Information Alliance, Inc. Names Michelle Puhlick as Interim Executive Director

WEST HARTFORD, Conn.--(BUSINESS WIRE)--Health Information Alliance, Inc. (HIA) — the operating entity charged with running Connecticut’s Health Information Exchange (HIE), Connie — today announced that Michelle Puhlick will become interim executive director and chief operating officer effective immediately, succeeding Jenn Searls, who is stepping down as part of an established succession plan. Puhlick has served as the organization’s chief operating officer since Connie’s inception in 2021. The...
-

Ascend and M1X Global Complete First Institutional Repo on Stellar Using USDM1 Secured Sovereign Bond

NEW YORK--(BUSINESS WIRE)--Ascend Markets, LLC, a wholly owned subsidiary of PSG Digital Labs, Inc. (“Ascend”), and M1X Global today announced the successful completion of the first institutional repurchase agreement (repo) on the Stellar network. The transaction utilized USDM1, a US dollar-denominated sovereign bond issued natively onchain and secured 1:1 by short-duration US Treasuries, and marks a milestone in bringing institutional secured financing onto the Stellar network, one of the long...